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We compared total body irradiation (TBI, 700 cGy)/cyclophosphamide (Cy, 3.6 g/m2)/simustine (250 mg/m2)
plus antithymocyte globulin (ATG) (TBI/Cy plus ATG) with cytarabine (8 g/m2)/i.v. busulfan (Bu, 9.6 mg/kg)/Cy
(3.6 g/m2)/simustine (250 mg/m2) plus ATG (modiﬁed Bu/Cy plus ATG) as preparative therapy in T cellere-
plete haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for acute leukemia. From August
2009 to August 2013, 38 consecutive patients using TBI/Cy plus ATG regimen for T cellereplete haplo-HSCT
(TBI group) at our center were eligible, which contained 28 high-risk and 10 standard-risk patients. A nested
case-control study was designed. Seventy-seven patients using modiﬁed Bu/Cy plus ATG regimen (Bu group)
were randomly selected in a 1 to 3:1 ratio matching for age, disease and status, year of HSCT (2 years), and
length of follow-up. Only 1 graft failure occurred in the TBI group. The incidence and time of neutrophil and
platelet engraftment were comparable between the 2 groups. Severe grades III/IV graft-versus-host disease
was observed in 13.4% of Bu group and only 2.6% of TBI group (P ¼ .083). More toxicity of the liver (37.7%
versus 10.5%; P ¼ .002) and more hemorrhagic cystitis occurred in the Bu group (49.3% versus 23.7%, P ¼ .008).
Diarrhea was more common in the TBI group (44.7% versus 22.1%; P ¼ .031). No signiﬁcant differences were
found in the 2-year incidences of relapse (26.5% for TBI group versus 32.3% for Bu group, P ¼ .742), 1-year
transplant-related mortality (12.6% versus 16.2%, P ¼ .862), 2-year overall survival (60.2% versus 57.0%,
P ¼ .937), and 2-year incidence of disease-free survival (57.9% versus 56.6%, P ¼ .845) between the 2 groups.
We conclude that the TBI/Cy plus ATG regimen seems to be feasible in T cellereplete haplo-HSCT, which
promotes stable engraftment and a lower incidence of liver toxicity and hemorrhagic cystitis. However, longer
follow-up is necessary to determine the late relapse rate and late toxicity.
 2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION in sibling and unrelated donor transplantation. TBI can
Advances in haploidentical transplantation have allowed
for the use of hematopoietic stem cell transplantation (HSCT)
in many patients without an HLA-identical donor or who ur-
gently require transplantation [1-7]. Busulfan (Bu) in combi-
nationwith cyclophosphamide (Bu/Cy) is themost frequently
used myeloablative preparative regimen in T cellereplete
haploidentical HSCT (haplo-HSCT), and encouraging results
havebeenreported [3-5,8,9].However, forpatientswithhigh-
risk hematological malignancies or Tcell acute lymphoblastic
leukemia (T-ALL) beyond the ﬁrst complete remission (CR1),
especially with advanced diseases, using the Bu/Cy regimen,
the cure ratewithhaploidentical transplantationhasnotbeen
satisfactory due to high rates of disease relapse and
transplant-related mortality (TRM), which prompted us to
attempt a newpretransplantation regimen for these patients.
Total body irradiation (TBI) in combination with Cy is
another commonly used myeloablative preparative regimenedgments on page 1181.
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14.04.012eradicate leukemic cells in “sanctuary sites” such as the cen-
tral nervous system or the testicles. Problems of drug excre-
tion or metabolism do not exist with TBI, unlike with Bu,
which has some toxic effects that are rare with TBI, such as
veno-occlusive disease of the liver, hemorrhagic cystitis, and
so on. Many studies of sibling or unrelated donors trans-
plantation have even found that the TBI/Cy regimen has some
advantages in reducing relapse and TRM, especially for ALL
and high-risk leukemia, compared with Bu-based regimens
[10-13]. However, there remains a lack of data on haplo-HSCT
using TBI/Cy regimen as myeloablative preparative regimen
with a T cellereplete graft. Low-dose TBI has been used in
nonmyeloablative preparative regimens for haplo-HSCT. In-
vestigators from Johns Hopkins University designed a TBI-
based nonmyeloablative preparative regimen consisting of
ﬂudarabine, TBI (2 Gy), and Cy pre- and post-transplantation
followed by a T cellereplete (unmanipulated) bone marrow
graft. This approach is effective for achieving donor engraft-
ment and immunological tolerance [14]. These promising
experiences of nonmyeloablative TBI-based regimens
prompted us to investigate the feasibility of TBI-based mye-
loablative regimen in T cellereplete haplo-HSCT.erican Society for Blood and Marrow Transplantation.
Table 1
Patient Characteristics
Variable TBI Group
(n ¼ 38)
Bu Group
(n ¼ 77)
P
Median age (range) 20 (13-46) 24 (8-51) .283
Gender .090
Male 30 (78.9) 48 (62.3)
Female 8 (21.1) 29 (37.7)
HSCT  7 mo from diagnosis 25 (65.8) 40 (51.9) .169
Diagnosis .030
AML 6 (15.8) 28 (36.4)
ALL 32 (84.2) 49 (63.6)
Disease status
Standard risk (T-ALL in CR1) 10 (26.3) 30 (39.0) .215
High risk 28 (73.4) 47 (61.0)
ALL 22 (57.9) 19 (24.7) .002
To achieve CR after 3
courses of chemotherapy
4 (10.5) 2 (2.6)
CR3 0 (0) 3 (3.9)
Not in remission 17 (44.8) 14 (18.2)
CR2 with previous HSCT 1 (2.6) 0 (0)
AML 6 (15.5) 28 (36.3)
To achieve CR after 3
courses of chemotherapy
2 (5.3) 4 (5.2)
CR3 1 (2.6) 4 (5.2)
Not in remission 0 (0) 17 (22.1)
CR2 with previous HSCT 3 (7.9) 3 (3.9)
Sex donor/recipient .060
Matched 19 (50.0) 43 (55.8)
Mismatched 19 (50.0) 34 (44.2)
HLA mismatched .825
1 locus 4 (10.5) 7 (9.1)
2 loci 13 (34.2) 22 (28.6)
3 loci 21 (55.3) 48 (62.3)
ABO blood type 1.000
Identical 23 (60.5) 46 (59.7)
Nonidentical 15 (39.5) 31 (40.3)
ATG dose 1.000
6 mg 11 (28.9) 22 (28.6)
10 mg 27 (71.1) 55 (71.4)
Median CD34þ cells 106/kg
(range)
2.55 (.67-5.89) 2.82 (1.04-6.72) .277
Median MNC 108/kg (range) 7.85 (5.89-15.43) 7.85 (5.08-14.5) .749
Prophylactic DLI 15 (39.5) 35 (45.5) .697
AML indicates acute myelocytic leukemia; MNC, mononuclear cell count.
Values are number of incidences with percents in parentheses unless
otherwise noted.
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and Cy plus antithymocyte globulin (ATG) to recipients of
T cellereplete haplo-HSCT for high-risk leukemia or T-ALL.
The aim of this studywas to retrospectively evaluatewhether
the TBI/Cy plus ATG regimen was well tolerated and sufﬁ-
ciently immunosuppressive for engraftment in T cellereplete
haplo-HSCT. A nested case-control study was designed to
compare the transplant outcomes between patients using
TBI/Cy plus ATG regimen with those using our conventional
modiﬁed Bu/Cy plus ATG regimen in T cellereplete haplo-
HSCT. The TBI/Cy plus ATG regimen may provide an alterna-
tive to patients who are not suitable candidates for Bu-based
regimens.
METHODS
Patients and Control Subjects
From August 2009 to August 2013, 38 consecutive patients with acute
leukemiawho used a TBI/Cy plus ATG regimen (TBI group) as described below
forTcellerepletehaploidenticalHSCTatourcenterwereeligible.Diseasestatus
at transplantation was deﬁned as “standard risk” if patients were in CR1 or
second complete remission (CR2) of acute leukemia without the history of
HSCT. Patients were categorized as “high risk” if they achieved CR after 3
course of chemotherapy [15], were inmore than the third complete remission
(CR3) of acute leukemia, were not in remission, and were in CR2 but with a
history of HSCT (autologous or allo-HSCT). Among the 38 patients using TBI/Cy
plus ATG regimen, 28 patients were classiﬁed as “high risk” and 10 patients as
“standard risk.” Although the risk category in this study was not according to
cytogenetics, all 10 standard-risk patients were diagnosed with T-ALL in CR1
without any cytogenetic abnormalities, whereas adverse cytogenetic abnor-
malities were only seen in high-risk patients. Of the 28 high-risk patients, 4
patients had t(9;22) and 1 patient had t(4;11) abnormalities.
To choose control subjects using modiﬁed Bu/Cy plus ATG regimen as
described below for T cellereplete haplo-HSCT, a nested case-control study
was designed. Using “risk set sampling” [16], we randomly selected control
subjects in a 1 to 3:1 ratiomatching for age, disease and status (high-risk acute
leukemia or T-ALL in CR1 without cytogenetic abnormalities), year of HSCT
(2 years), and length of follow-up. Finally, 77matched control subjects using
modiﬁed Bu/Cy plus ATG regimen (Bu group) were chosen for the analyses.
Among them, 47 patients had high-risk leukemia and 30 patients were diag-
nosed with T-ALL in CR1 without cytogenetic abnormalities. Of the high-risk
patients in the Bu group, 2 patients had t(9;22) and 1 patient t(4;11) abnor-
malities. The characteristics of TBI patients and control subjects are summa-
rized in Table 1. The ethics committee of the Peking University People’s
Hospital approved the study protocol. Informed consent was obtained ac-
cording to the Declaration of Helsinki.
Conditioning Regimen
Patients in the TBI group received conditioning with TBI (770 cGy) with
particle shieldingof the lungs (600 cGy)onday6, andpatients in theBugroup
receivedcytarabine (4g/m2 i.v. perday)ondays10 to9,Bu(3.2mg/kg i.v. per
day) on days 8 to 6, both followed by Cy (1.8 g/m2 i.v. per day) on days 5
and4, simustine (Me-CCNU;250mg/m2p.o.) onday3, and rabbitATG (Sang
Stat, Lyon, France) on days5 to 2.
The total dose of ATG was 10 mg/kg for patients with T-ALL in CR1 in
both TBI and Bu groups. For high-risk patients in both groups, the total dose
of ATG was 6 or 10 mg/kg. The total dose of ATG was administered intra-
venously over 10 hours in 4 divided doses daily for 4 days (day 5 to 2).
Hyperhydration and alkalization were administered from day 6 until
the last dose of Cy was given. During the 2 days when patients received Cy,
mesna was given for hemorrhagic cystitis prophylaxis.
Stem Cell Graft Harvest
Donors were primed with recombinant human granulocyte colony-
stimulating factor (ﬁlgrastim; Kirin, Japan; 5 to 10 mg/kg/d s.c.) for 5 to 6
consecutive days. Bonemarrowwas harvested on the fourth day (day 0), and
peripheral blood stem cells were collected with a blood cell separator
(Spectra LRS; Cobe BCT Inc, Lakewood, CO) on the ﬁfth day (day 2) and on the
sixth day (day 3) if needed.
Graft-Versus-Host Disease Prophylaxis and Treatment
All transplant recipients received cyclosporine A (CsA), mycophenolate
mofetil, and short-term methotrexate for graft-versus-host disease (GVHD)
prophylaxis. Theprimarydosageof CsAwas 2.5mg/kg/d i.v. fromday9until
bowel function returned to normal. At that point, patients were switched to
oral CsA. Whole blood CsA concentration was monitored weekly usingﬂuorescence polarization immunoassay, and the dosage was adjusted to a
blood concentration of 150 to 250 ng/mL. When there was no evidence of
GVHD by day þ180, CsA dosage was reduced gradually. When GVHD did
occur, CsA was continued. Mycophenolate mofetil was administered orally,
.5 g every 12 hours, from day 9 to day þ30, was tapered from .5 g every
12 hours to .25 g every 12 hours on day þ30, and was discontinued over
daysþ45 toþ60. Thedosageofmethotrexatewas15mg/m2, administered i.v.
on day þ1, and 10 mg/m2 on days þ3, þ5 and þ11. Acute GVHD was treated
with steroids (methylprednisolone .5 to 1 mg/kg/d). For inadequate or no
response to primary therapy, anti-CD25monoclonal antibodies (basiliximab;
Novartis Pharma AG, Basle, Switzerland; or Zenapax; Hoffmann-La Roche
Corp,Nutley, NJ)were administered to thepatient. ChronicGVHDwas treated
with CsA and steroids.
Regimen-Related Toxicity
According to the World Health Organization toxicity scale [17], the inci-
dence and severity of mucositis, diarrhea, fever, pain, hepatic, renal, and
central nervous systemtoxicitieswere estimated fromday5 todayþ15. The
maximum score for each organ systemwas recorded.
Supportive Care
All patients were hospitalized in rooms with high-efﬁciency particle-
arresting airﬁlters and receivedprophylactic antibiotics and antifungalswith
oral trimethoprim-sulfamethoxazole and ﬂuconazole starting on day 10.
Ganciclovir (5 mg/kg) was administered i.v. twice daily from days 5 to 2.
Patients were monitored weekly for cytomegalovirus (CMV) by DNA (real-
time PCR). All patients with 2 consecutive tests positive for CMV-DNA were
treated with ganciclovir at a standard dose of 5 mg/kg twice daily until the
H. Fu et al. / Biol Blood Marrow Transplant 20 (2014) 1176e11821178CMV-DNAwas negative on 2 occasions. In cases of severe myelotoxicity due
to ganciclovir therapy or CMV refractoriness, therapy was changed to fos-
carnet (90 to 120 mg/kg/d).
Patients received red blood cell transfusions if their hemoglobin levels were
below 70 g/L or platelet transfusions if their platelet levels dropped below
20  109/L. All blood products were ﬁltered and irradiated before infusion.
Granulocyte colony-stimulating factor (ﬁlgrastim 5 mg/kg/d, s.c.) was adminis-
tered to all recipients from dayþ6 until myeloid recovery.
Prevention and Treatment of Relapse
A modiﬁed donor lymphocyte infusion (mDLI) was selected as prophy-
laxis or therapy against leukemia relapse and was performed according to
previously describedmethods [18,19]. TherapeuticDLIwas performed for the
treatmentof hematological orextramedullary relapseafterHSCT. Preemptive
DLI was performedwhenminimal residual diseasewas diagnosed to prevent
relapse after HSCT. For patients with a high-risk leukemia pre-HSCT, pro-
phylactic DLI was performed before relapse and positive minimal residual
disease from days 30 to 60 after HSCT.
Analysis of Chimerism
Hematopoietic chimerism was evaluated by ﬂuorescein in situ hybridi-
zation for sex-mismatched patientedonor pairs and by PCR ampliﬁcation of
short tandem repeats for sex-matched pairs using peripheral blood samples
from the donor and the recipient. Complete donor chimerismwas deﬁned as
the presence of only donor-type hematopoietic cells after allo-HSCT.
Deﬁnitions
Neutrophil engraftment was deﬁned as absolute neutrophil count of
.5  109/L or more for 3 consecutive days and platelet engraftment as
20  109/L or more for 7 consecutive days without transfusion. Primary
engraftment failure was deﬁned as the absence of donor-derived myeloid
cells in patients surviving beyond day 28 after transplantation. The diag-
nosis and grading of GVHD was performed according to published criteria
[20,21]. Time to GVHD was deﬁned as the time from allo-HSCT to the onset
of any grade of GVHD; acute GVHD was censored at day 100 after HSCT and
chronic GVHD was censored at last follow-up. Disease relapse was deﬁned
as hematological relapse. TRM was deﬁned as death from any cause other
than relapse. Disease-free survival (DFS) was deﬁned as survival in a state of
continuous CR.
Statistical Analysis
Patient-, disease- and transplant-related variables of the 2 groups (Bu
group and TBI group) were compared, using the chi-square statistic for
categorical variables and the Mann-Whitney test for continuous variables.
Cumulative incidence curves were used in a competing risks setting, with
death treated as a competing event to calculate probabilities of GVHD,
neutrophil and platelet recovery, Epstein-Barr virus (EBV) and CMV reac-
tivation, TRM, and relapse. The probabilities of overall survival (OS) and DFS
were estimated by the Kaplan-Meier method. Factors differing in distribu-
tion between the 2 groups with P < .10 and factors associated with a
nonrestrictive P ¼ .15 in univariate analyses were included in the multi-
variate analyses, using the proportional subdistribution hazard regression
model of Fine. The potential interaction between main effect and all sig-
niﬁcant covariates was tested. No interactions were detected.
SAS version 8.2 (SAS Institute, Cary, NC) and S Plus 2000 (Mathsoft,
Seattle, WA) were used for most analyses. Statistical signiﬁcance was
determined at the .05 level. All P values were 2 sided. A 95% conﬁdence
interval (95% CI) was calculated to compute the standard error. The last
follow-up was carried out on September 30, 2013.
RESULTS
Engraftment and Chimerism
No patient died before day 28. Thirty-seven of 38 patients
(97.4%) in the TBI group and all 77 patients (100%) in the Bu
group achieved sustained neutrophil engraftment at a me-
dian of 13 days (range, 10 to 21 days) and 12 days (range, 8 to
21 days), respectively. The incidence and median time of
neutrophil engraftment were comparable between the 2
groups (P ¼ .159 and .442, respectively).
Except for 1 patient with primary engraftment failure,
platelet engraftment failure occurred in 5 patients in the TBI
group (15.8%) and 6 patients in the Bu group (7.8%) until day
60. Platelet engraftment for the rest of the patients occurred
at a median of 19 days (range, 8 to 59 days) in the TBI groupand 16 days (range, 8 to 46 days) in the Bu group. There was
no signiﬁcant difference in the incidence and median time of
platelet engraftment between the 2 groups (P¼ .184 and .100,
respectively).
Rapid achievement of full donor chimerism was also
conﬁrmed in 37 of 38 patients (97.4%) in the TBI group and all
patients in the Bu group by day þ30. No graft loss has
occurred in surviving patients so far.
Only 1 patient in the TBI group with primary engraftment
failure received a second transplantation from the same
donor on day 29 after conditioning with Cy (1000 mg/m2/
d  2 days), ﬂudarabine (30 mg/m2/d  4 days), and anti-
CD25 monoclonal antibodies. However, no sustained
neutrophil engraftment was conﬁrmed until the patient died
of severe infection on day 32 after the second
transplantation.
Regimen-Related Toxicity
All patients tolerated the conditioning regimen. The most
common toxicities were nausea, diarrhea, and fever in both
groups. The incidences of total regimen-related toxicity were
94.7% and 92.2% in TBI and Bu group, respectively (P¼ 1.000).
Diarrhea was more common in the TBI group (44.7% versus
22.1%; P ¼ .031) However, there was no signiﬁcant difference
for severe diarrhea grade 3 or 4 between the 2 groups. In
addition, incidence for toxicity of liver was higher in the Bu
group (37.7% versus 10.5%; P ¼ .002). Other toxicities
affecting the renal, heart, pulmonary, central nervous sys-
tem, and mucous membranes were observed to the same
extent in both groups (Table 2). No veno-occlusive disease of
the liver was observed in both groups, and there was no
regimen-related death in both groups.
Virus Infections and Hemorrhagic Cystitis
Thirty-three patients in the TBI group and 56 patients in
the Bu group experienced CMV viremia until day 100. The
100-day cumulative incidences of CMV viremia were similar:
86.8% (95% CI, 75.4% to 98.2%) for the TBI group versus 72.7%
(95% CI, 62.6% to 82.8%) for the Bu group (P¼ .666). However,
the median time to onset of CMV viremia between the 2
groups was also similar: day 26 (range, days 10 to 60) in the
TBI group and day 31 (range, days 16 to 80) in Bu group
(P¼ .106). Six patients experienced EBV viremia until day 100
in both groups with the median time of day 47 (range, days
35 to 56) in the TBI group and day 45 (range, days 35 to 59) in
the Bu group. The 100-day cumulative incidences of EBV
viremia were comparable between the 2 groups: 15.8% (95%
CI, 4% to 27.5%) in the TBI group versus 7.8% (95% CI, 1.8% to
13.8%) in the Bu group (P ¼ .188). However, hemorrhagic
cystitis occurred more frequently in the Bu group. The 180-
day cumulative incidences of hemorrhagic cystitis were
49.3% (95% CI, 38.1% to 60.5%) and 23.7% (95% CI, 10.0% to
37.4%), respectively (P ¼ .008) (Figure 1), and the median
days to onset of hemorrhagic cystitis were day 42 (range,
days 12 to 61) and day 26 (range, days 9 to 56), respectively
(P ¼ .142).
Graft-Versus-Host Disease
Acute GVHD developed in 26 patients in the TBI group
(grade I in 13 patients, II in 12 patients, and III and IV in 1
patient). Fifty-three patients in the Bu group developed acute
GVHD (grade I in 26 patients, II in 19 patients, and III and IV in
8 patients). The incidences of grades I to IV acute GVHDwere
69.6% (95% CI, 54.1% to 85.1%) and 68.8% (95% CI, 58.3% to
79.3%) for the TBI and Bu groups, respectively (P ¼ .864).
Table 2
Regimen-Related Toxicity
Variable TBI Group
(n ¼ 38)
Bu Group
(n ¼ 77)
P
Nausea and vomiting .908
Grade 1 12 (31.6) 28 (36.4)
Grade 2 14 (36.9) 25 (32.5)
Grade 3 11 (28.9) 19 (24.6)
Grade 4 1 (2.6) 5 (6.5)
Diarrhea .031
Grade 1 2 (5.3) 14 (18.2)
Grade 2 18 (47.4) 16 (20.8)
Grade 3 7 (18.4) 16 (20.8)
Grade 4 0 (0) 1 (1.3)
Fever .688
Grade 1 6 (15.8) 12 (15.6)
Grade 2 17 (44.7) 28 (36.4)
Grade 3 1 (2.6) 2 (2.6)
Grade 4 0 (0) 0 (0)
Mucositis .525
Grade 1 3 (7.9) 2 (2.6)
Grade 2 1 (2.6) 11 (14.3)
Grade 3 4 (10.5) 6 (7.8)
Grade 4 2 (5.3) 1 (1.3)
Liver .002
Grade 1 3 (7.9) 2 (2.6)
Grade 2 1 (2.6) 19 (24.7)
Grade 3 0 (0) 4 (5.2)
Grade 4 0 (0) 4 (5.2)
Renal .852
Grade 1 2 (5.3) 1 (1.3)
Grade 2 0 (0) 0 (0)
Grade 3 0 (0) 0 (0)
Grade 4 0 (0) 0 (0)
Pain .655
Grade 1 1 (2.6) 0 (0)
Grade 2 3 (7.9) 2 (2.6)
Grade 3 1 (2.6) 0 (0)
Grade 4 0 (0) 0 (0)
Skin .784
Grade 1 1 (2.6) 5 (6.5)
Grade 2 0 (0) 0 (0)
Grade 3 0 (0) 0 (0)
Grade 4 0 (0) 0 (0)
Values are number of incidences with percents in parentheses.
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47.7%) of the TBI group and 40.3% (95% CI, 29.2% to 51.4%) of
the Bu group (P¼ .373). The incidence of grades III to IV acuteFigure 1. The cumulative incidences of hemorrhagic cystitis after T
cellereplete haplo-HSCT. Hemorrhagic cystitis occurred signiﬁcantly more
frequently in the Bu group (patients using modiﬁed Bu/Cy plus ATG regimen)
compared with the TBI group (patients using TBI/Cy plus ATG regimen).GVHDwas slightly higher in the Bu group (13.4% [95% CI, 5.5%
to 20.5%]) than in the TBI group (2.6% [95% CI,2.5% to 7.7%];
P ¼ .083). The 1-year incidences of chronic GVHD were
similar between the 2 groups: 61.4% (95% CI, 44.1% to 78.7%)
versus 52.7% (95% CI, 41.1% to 64.3%) (P ¼ .232).Relapse and TRM
Relapse was deﬁned as hematological relapse. Until the
date of analysis, 9 patients in the TBI group and 22 patients in
the Bu group relapsed. The 2-year cumulative incidences of
relapse for the 2 groups were not signiﬁcantly different:
26.5% (95% CI, 11.3% to 41.7%) for the TBI group versus 32.3%
(95% CI, 21.0% to 43.4%) for the Bu group (P ¼ .742). All 9
relapsed patients (100%) in the TBI group and 21 of 22
relapsed patients (95.5%) in the Bu group were in high-risk
status before HSCT. For high-risk patients, no signiﬁcant
difference in 2-year cumulative incidences of relapse was
observed between the 2 groups: 35.4% (95% CI, 16.2% to
54.6%) for the TBI group versus 44.5% (95% CI, 29.7% to 59.3%)
for the Bu group (P¼ .548). However, not only for all patients
but also for high-risk patients, there was a trend toward a
higher relapse rate in the Bu group. Seven of 9 relapsed pa-
tients (77.8%) in the TBI group and 18 of 22 relapsed patients
(81.8%) in the Bu group died, and the remaining patients are
currently alive in relapse-free status after chemotherapy and
mDLI.
Five of 38 patients and 13 of 77 patients died from
transplantation-related complications at a median of
232 days (range, 28 to 589 days) in the TBI group and 140 days
(range, 42 to 511 days) in the Bu group. The 1-year cumulative
incidences of TRM were not signiﬁcantly different between
the TBI and Bu groups for all patients (12.6% [95% CI, 6% to
24.6%] versus 16.2% [95% CI, 7.7% to 24.7%]; P ¼ .862) or for
high-risk patients (12.0% [95% CI, .7% to 25.3%] versus 17.8%
[95% CI, 6.7% to 28.9%]; P¼ .862) (all P¼ .784). Causes of TRM
were severe infections (n¼ 3), refractory acute GVHD (n¼ 1),
andgraft failure (n¼1) for the TBI groupand severe infections
(n¼ 8), refractory acute GVHD (n¼ 4), and suicide (n¼ 1) for
the Bu group. Infection and acute GVHD were the causes of
death in most patients in both groups.OS and DFS
After the median follow-up of 598 days (range, 60 to
1471 days) for survivors in the TBI group and 699 days
(range, 77 to 1491 days) for survivors in the Bu group
(P ¼ .11), the 2-year OS was 60.2% (95% CI, 40.9% to 79.5%) for
the TBI group and 57.0% (95% CI, 44.8% to 69.1%) for the Bu
group (P ¼ .937) (Figure 2A). The 2-year DFS was 57.9% (95%
CI, 38.7% to 77.1%) and 56.6% (95% CI, 38.7% to 68.3%) for the
TBI and Bu groups, respectively (P ¼ .845) (Figure 3A). For
high-risk patients, the 2-year OS was 52.5% (95% CI, 30.2% to
74.8%) and 41.1% (95% CI, 26.0% to 56.2%) (P ¼ .509)
(Figure 2B) and the 2-year DFS was 49.5% (95% CI, 27.2% to
71.8%) and 39.9% (95% CI, 25.2% to 54.6%) (P ¼ .419)
(Figure 3B) for the TBI and Bu groups, respectively. Although
all of differences were not signiﬁcant, the 2-year OS and DFS
of the TBI group had a higher trend than the Bu group,
especially for high-risk patients. Multivariate analysis
showed refractory/relapsed status pre-HSCT (relative
risk ¼ 4.568; 95% CI, 1.75 to 11.922; P ¼ .002), grades III to IV
acute GVHD (relative risk ¼ 2.391; 95% CI, 1.193 to 4.789;
P¼ .014), and EBV viremia (relative risk¼ 3.741; 95% CI, 1.937
to 7.227; P < .001) were associated with signiﬁcantly
worse OS.
Figure 2. (A) Probability of OS according to preparative regimen after T cellereplete haplo-HSCT. Patients in the TBI group used TBI/Cy plus ATG regimen; patients in
the Bu group used modiﬁed Bu/Cy plus ATG regimen. (B) Probability of OS for high-risk patients according to preparative regimen after T cellereplete haplo-HSCT.
Patients in the TBI group used TBI/Cy plus ATG regimen; patients in the Bu group used modiﬁed Bu/Cy plus ATG regimen.
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In present study, we pioneered the combination of TBI/Cy
plus ATG as the myeloablative preparative regimen for
T cellereplete haplo-HSCT and ﬁrst compared TBI with Bu
combinedwith Cy for T cellereplete haplo-HSCT. Historically,
the TBI/Cy regimen has been widely used in matched sibling
and unrelated donor transplantation. However, the feasibility
of the TBI/Cy regimen for Tcellereplete haplo-HSCT has yet to
be evaluated. In an earlier study, Bacigalupo et al. [22] studied
the impact of preparative regimens with or without ATG on
chronic GVHD and used a TBI/Cy regimen in part in 33 re-
cipients of T cellereplete haplo-HSCT. However, they neither
mentioned how many recipients of haplo-HSCT used this
regimen nor described the efﬁcacy of the TBI/Cy regimen in
haplo-HSCT. It is difﬁcult to conclude that TBI/Cy is feasible for
T cellereplete haplo-HSCT regimen according to this study.
Based on our center’s experience, results of 8 patients with
high-risk leukemia or T-ALL using TBI-based regimens for
T cellereplete haplo-HSCT were reported [23]. The combi-
nation of TBI/Cy or ﬂudarabine plus ATG were used in this
study. All 8 patients not only achieved stable neutrophil and
platelet engraftment but also acquired satisfactory TRM and
OS, which suggested that TBI-based regimens were a prom-
ising conditioning regimen for T cellereplete haplo-HSCTFigure 3. (A) Probability of DFS according to preparative regimen after T cellereplete h
the Bu group used modiﬁed Bu/Cy plus ATG regimen. (B) Probability of DFS for high-r
Patients in the TBI group used TBI/Cy plus ATG regimen; patients in the Bu group us[23]. However, these results were limited because of
different combinations, small number of patients, and short
period of follow-up. Also, no comparative analysis between
the TBI/Cy and Bu/Cy regimens for T cellereplete haplo-HSCT
has been reported until now. In the present study, compara-
tive analysis of TBI/Cy plus ATG versus modiﬁed Bu/Cy plus
ATG regimenwas performed, and the results showed at least
comparable safety and efﬁcacy of TBI/Cy plus ATG regimen as
modiﬁed Bu/Cy plus ATG regimen for myeloablative
T cellereplete haplo-HSCT.
As to the ﬁrst point, engraftment is a relevant issue in
haplo-HSCT [2,24,25]. In the present study, prompt and
sustained achievement of neutrophil engraftment and full-
donor chimerism was documented in 37 of 38 patients
(97.4%) in the TBI group, which was comparable with the Bu
group. Both the incidence and time of platelet engraftment
were also similar between the 2 groups. The results suggest
that the combination of TBI/Cy plus ATG seems to be enough
to achieve the degree of immunosuppression needed for
engraftment in T cellereplete haplo-HSCT. Only 1 patient
with primary graft failure in the TBI group received a lower
transfused count of CD34þ cells (1.76  106/kg) compared
with the median count of 3.09  106/kg, which might be 1
cause of graft failure.aplo-HSCT. Patients in the TBI group used TBI/Cy plus ATG regimen; patients in
isk patients according to preparative regimen after T cellereplete haplo-HSCT.
ed modiﬁed Bu/Cy plus ATG regimen.
H. Fu et al. / Biol Blood Marrow Transplant 20 (2014) 1176e1182 1181Tolerance is another important factor in the choice of
conditioning regimen. In previous randomized trials or
retrospective analyses of Bu/Cy versus TBI/Cy in sibling and
unrelated donor transplantation, early toxicities were an
important problem with Bu-containing regimens. Veno-
occlusive disease and hemorrhagic cystitis occurred more
frequently in patients receiving Bu [26,27]. In our study, no
veno-occlusive disease occurred in either treatment group,
but more liver toxicities and hemorrhagic cystitis were
observed in theBugroup. BuandCyaremainlymetabolized in
the liver, and both toxic Cy metabolites and Bu can decrease
the levels of glutathione [28,29]. Combining these2 alkylating
agents may result in an exacerbated risk for serious hepatic
injuries [28]. However, these problems of drug excretion or
metabolism do not exist with TBI. TBI may cause less bladder
mucosa injury than Bu, which contributed to less hemor-
rhagic cystitis.
In the present study, more regimen-related diarrhea
occurred in the TBI group, but the risk of severe regimen-
related diarrhea grade 3 or 4 was comparable for the 2
groups, which did not decrease the tolerance of the TBI
regimen. The incidences of acute GVHD were also similar for
the 2 treatment groups. Patients in the TBI group even had the
trend of lower risk of developing grades III to IV acute GVHD.
Only 2.6% of the TBI group developed grades III to IV acute
GVHD, which was much lower than the Bu group (13.4%).
However, the difference was not signiﬁcant. Preparative regi-
mens that cause more tissue damage may contribute to the
higher incidence of GVHD [30,31]. The reduced dose of TBI in
the present study compared with most other TBI-based mye-
loablative regimens may be the reason for good tolerance
[11,12,26]. Further, TRM in the TBI group was as low as that of
the Bu group. The combination of TBI/Cy plus ATG as a pre-
parative regimen showed good tolerance in T cellereplete
haplo-HSCT. However, some complications, such as secondary
malignancies, alopecia, cataracts, gonadal failure, endocrino-
logical disturbances, and thyroid dysfunction, appeared late
after transplantation, and we did not evaluated these late
complications because of the short period of follow-up in the
present study. Longer follow-up isneeded topreciselycompare
late complications related to the conditioning regimen.
Long-term antileukemic effect is one of the most impor-
tant factors in the choice of preparative regimen. In matched
sibling and unrelated donor transplantation, several pro-
spective and retrospective studies were aimed at comparing
TBI and Bu associatedwith Cy as a preparative regimen.Many
studies found a signiﬁcant survival advantage for patients
treated with TBI conditioning, especially for ALL. The TBI/Cy
regimenwas also the favorable conditioning regimen for ALL
in many centers for matched sibling and unrelated donor
transplantation [12]. Our study found similar relapse, DFS,
and OS rates for the TBI and Bu groups, but that was limited
because of the short period of follow-up. Although therewere
more patients with ALL in the TBI group, patients in the TBI
group did have the trend of higher 2-year OS and DFS than
patients in the Bu group, especially high-risk patients. The
exciting probabilities of 2-year OS and DFS rates (52.5% and
49.5%) in the TBI group for high-risk patients suggested the
TBI/Cy plus ATG regimen was feasible in eradication of leu-
kemia and was a promising regimen for T cellereplete haplo-
HSCT,warranting further study. Longer follow-up is needed to
conﬁrm the long-term antileukemic effect of TBI/Cy plus ATG
regimen for T cellereplete haplo-HSCT. In addition, this is a
young group of patients, withmedian ages of 20 and 24 years,
and results from this experience cannot be extrapolated toolder individuals. Further study is necessary to determine the
feasibility of TBI/Cy plus ATG regimen in older patients,
especially for patients older than 50 years for T cellereplete
haplo-HSCT.
In conclusion, our preliminary results demonstrate that
the TBI/Cy plus ATG regimen seems to be a promising and
alternative conditioning regimen for recipients of
T cellereplete haplo-HSCT. However, a prospective random-
ized controlled trial and longer follow-up is necessary to
compare the safety and efﬁcacy of TBI/Cy plus ATG with
modiﬁed Bu/Cy plus ATG.ACKNOWLEDGMENTS
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